Accordingly, clinical trials using MEK inhibitors alone have been far less successful than for BRAFV600E inhibitors in BRAFV600E melanoma.41, 42 By using a genetic approach, we were able to circumvent these issues as a means of precisely determining if inactivation of MEK could be an effective treatment for melanoma. This evidence concerns the gene MAP2K7 and melanoma.